MANUEL JIMENEZ: Open Payments
NPI 1619412350 · SUNNYSIDE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$884 in 38 payments from 11 companies in 2025. Trend: 2023 $642 · 2024 $397 · 2025 $884
Food & beverage: $884
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $223 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $157 |
| Lilly USA, LLC | 4 | $110 |
| Sumitomo Pharma America, Inc. | 4 | $104 |
| Novo Nordisk Inc | 3 | $69 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $52 |
| KYOWA KIRIN, INC. | 3 | $52 |
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| Novartis Pharmaceuticals Corporation | 1 | $26 |
| PFIZER INC. | 1 | $23 |
Products named: CAPLYTA, MOUNJARO, GEMTESA, FARXIGA, Kerendia, CRYSVITA, REXULTI, ENTRESTO.
Industry payments across WA — which companies pay providers there.
